Results of the IELSG32 trial at a median follow-up of 88 months demonstrate that matrix followed by autologous transplant is associated with excellent survival and neurotolerability in patients with primary CNS lymphoma
Authors
Calimeri, T.Cwynarski, K.
Pulczynski, E.
Fox, C. P.
Schorb, E.
Steffanoni, S.
Foppoli, M.
Celico, C.
Falautano, M.
Nonis, A.
La Rosee, P.
Binder, M.
Fabbri, A.
Ilariucci, F.
Krampera, M.
Roth, A.
Hemmaway, C.
Johnson, P. W.
Linton, Kim M
Pukrop, T.
Gorlov, J.
Balzarotti, M.
Hess, G.
Keller, U.
Stilgenbauer, S.
Panse, J.
Tucci, A.
Orsucci, L.
Pisani, F.
Zanni, M.
Krause, S. W.
Schmoll, H. J.
Hertenstein, B.
Rummel, M.
Smith, J.
Thurner, L.
Cabras, G.
Pennese, E.
Ponzoni, M.
Deckert, M.
Politi, L. S.
Finke, J.
Ferranti, A.
Cozens, K.
Burger, E.
Ielmini, N.
Cavalli, F.
Zucca, E.
Illerhaus, G.
Ferreri, A. J. M.
Affiliation
Lymphoma Unit, Department of Onco-Hematology ,IRCCS SanRaffaele Scientific Institute ,Milan, Italy;Issue Date
2021